MCID: ANT024
MIFTS: 58

Anthrax Disease

Categories: Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Anthrax Disease

MalaCards integrated aliases for Anthrax Disease:

Name: Anthrax Disease 12 15 71
Anthrax 74 52 54 42 3 43 32
Ragpicker's Disease 52 71
Wool Sorter's Disease 52
Cutaneous Anthrax 71
Malignant Pustule 52
Malignant Edema 52
Siberian Plague 52
Gas Gangrene 71
Black Baine 52

Classifications:



External Ids:

Disease Ontology 12 DOID:7427
ICD9CM 34 022
MeSH 43 D000881
NCIt 49 C84565
SNOMED-CT 67 409498004
ICD10 32 A22 A22.9
UMLS 71 C0003175 C0003177 C0017105 more

Summaries for Anthrax Disease

NIH Rare Diseases : 52 Anthrax is an infection caused by the bacterium Bacillus anthracis. The severity of the condition, the associated signs and symptoms and the prognosis vary depending on which part of the body is involved (see below). Antibiotics can be used to treat all forms of anthrax. Antitoxin medications may also be used to treat some forms of the condition. Cutaneous (skin) anthrax occurs when the infection enters the body through a cut or sore on the skin. It is the most common type of anthrax and generally the least serious. Affected people may experience a group of small, itchy bumps; swelling around a sore; and/or a painless ulcer with a black center. These skin abnormalities are generally found on the face, neck, arms, or hands. With appropriate treatment, cutaneous anthrax is seldom fatal. Gastrointestinal anthrax is caused by eating undercooked meat from an infected animal. Signs and symptoms may include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, and a sore throat. Pulmonary (lung) anthrax occurs when anthrax spores are inhaled. It is the most deadly form of the condition. Early signs include flu-like symptoms, shortness of breath, nausea, and coughing up blood. As the condition advances, affected people may develop high fever, difficulty breathing, shock, and meningitis . Even with treatment, pulmonary anthrax may be fatal. Injection anthrax is spread by injecting illegal drugs. Signs and symptoms of this form of anthrax include redness and swelling at the sight of the infection. The condition may progress to shock, multiple organ failure and meningitis.

MalaCards based summary : Anthrax Disease, also known as anthrax, is related to oropharyngeal anthrax and inhalation anthrax, and has symptoms including fever, skin ulcer and poor appetite. An important gene associated with Anthrax Disease is ANTXR1 (ANTXR Cell Adhesion Molecule 1), and among its related pathways/superpathways are HIV Life Cycle and PEDF Induced Signaling. The drugs Promethazine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, lung lymph nodes and gastrointestinal tract, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin, located in lung lymph nodes or located in gastrointestinal tract, has material basis in Bacillus anthracis, transmitted by contact with infected animals or animal products, transmitted by airborne spores or transmitted by ingestion of undercooked meat from infected animals and has symptom skin ulcer, has symptom nausea, has symptom poor appetite, has symptom bloody diarrhea, has symptom fever or has symptom shortness of breath.

MedlinePlus : 42 Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick. Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria. Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria. Gastrointestinal, which affects the digestive system. You can get it by eating infected meat. Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk.

CDC : 3 Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Although it is rare, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products.

Wikipedia : 74 Anthrax is an infection caused by the bacterium Bacillus anthracis. It can occur in four forms: skin,... more...

Related Diseases for Anthrax Disease

Diseases related to Anthrax Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 oropharyngeal anthrax 34.4 ANTXR2 ANTXR1
2 inhalation anthrax 31.4 PRDX1 MKKS MAP2K3 FURIN APLF ANTXR2
3 gastrointestinal anthrax 31.2 PRDX1 NLRP1 FURIN ANTXR2 ANTXR1
4 cutaneous anthrax 30.4 PRDX1 MKKS MAP2K3 KIF1C FURIN ANTXR2
5 pertussis 29.5 MAPK14 MAPK1 ADCY10
6 gapo syndrome 11.6
7 pancreatic ductal adenocarcinoma 10.8
8 plague 10.6
9 meningitis 10.6
10 cholera 10.5
11 diphtheria 10.5
12 brucellosis 10.5
13 tularemia 10.5
14 variola major 10.4
15 smallpox 10.4
16 meningoencephalitis 10.4
17 mckusick-kaufman syndrome 10.4
18 ectropion 10.4
19 tetanus 10.3
20 cellulitis 10.3
21 vasculitis 10.3
22 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
23 rabies 10.3
24 cicatricial ectropion 10.3
25 toxic shock syndrome 10.3
26 carbuncle 10.3
27 mediastinitis 10.3
28 allergic hypersensitivity disease 10.3
29 lymphadenitis 10.3
30 hydrops, lactic acidosis, and sideroblastic anemia 10.2
31 bacterial infectious disease 10.2
32 pulmonary edema 10.2
33 cytokine deficiency 10.2
34 hyaline fibromatosis syndrome 10.2
35 typhoid fever 10.2
36 fibromatosis 10.2
37 foodborne botulism 10.2
38 vaccinia 10.2
39 encephalitis 10.2
40 3-methylglutaconic aciduria, type iii 10.1
41 body mass index quantitative trait locus 1 10.1
42 helix syndrome 10.1
43 endocarditis 10.1
44 disseminated intravascular coagulation 10.1
45 optic neuritis 10.1
46 neuritis 10.1
47 pneumonia 10.1
48 compartment syndrome 10.1
49 influenza 10.1
50 spondyloarthropathy 1 10.0

Graphical network of the top 20 diseases related to Anthrax Disease:



Diseases related to Anthrax Disease

Symptoms & Phenotypes for Anthrax Disease

Symptoms:

12
  • fever
  • skin ulcer
  • poor appetite
  • nausea
  • bloody diarrhea
  • shortness of breath

UMLS symptoms related to Anthrax Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Anthrax Disease according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.62 MAP2K3 MAPK1
2 Decreased viability GR00055-A-2 9.62 MAP2K3 MAPK1
3 Decreased viability GR00107-A-1 9.62 MAP2K1
4 Decreased viability GR00173-A 9.62 MAP2K3
5 Decreased viability GR00221-A-1 9.62 MAP2K4 MAPK1
6 Decreased viability GR00221-A-3 9.62 MAP2K1 MAP2K3 MAP2K4 MAPK1
7 Decreased viability GR00221-A-4 9.62 MAP2K4 MAPK1
8 Decreased viability GR00249-S 9.62 MAPK1
9 Decreased viability GR00301-A 9.62 MAP2K4
10 Decreased viability GR00342-S-1 9.62 MAPK1
11 Decreased viability GR00342-S-2 9.62 MAPK1
12 Decreased viability GR00342-S-3 9.62 MAPK1
13 Decreased viability GR00386-A-1 9.62 MAP2K3

MGI Mouse Phenotypes related to Anthrax Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ADCY10 ANTXR1 ANTXR2 APLF CASP1 LRP6
2 cardiovascular system MP:0005385 10.26 ADCY10 ANTXR1 ANTXR2 CASP1 FURIN MAP2K1
3 homeostasis/metabolism MP:0005376 10.15 ADCY10 APLF CASP1 LRP6 MAP2K1 MAP2K2
4 immune system MP:0005387 10.1 ANTXR1 ANTXR2 APLF CASP1 FURIN KIF1C
5 mortality/aging MP:0010768 10 ANTXR1 ANTXR2 CASP1 FURIN LRP6 MAP2K1
6 craniofacial MP:0005382 9.98 ANTXR1 LRP6 MAP2K1 MAP2K2 MAPK1 MKKS
7 digestive/alimentary MP:0005381 9.95 CASP1 FURIN LRP6 MAP2K1 MAP2K2 MAPK1
8 integument MP:0010771 9.86 CASP1 FURIN LRP6 MAP2K1 MAP2K2 MAP2K4
9 neoplasm MP:0002006 9.56 ANTXR1 CASP1 MAP2K1 MAP2K2 MAPK1 MAPK14
10 reproductive system MP:0005389 9.36 ADCY10 ANTXR1 ANTXR2 CASP1 KIF1C LRP6

Drugs & Therapeutics for Anthrax Disease

Drugs for Anthrax Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 4 60-87-7 4927
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
4 Vaccines Phase 4
5 Hypnotics and Sedatives Phase 4
6 Anesthetics Phase 4
7 Anti-Allergic Agents Phase 4
8 Histamine Antagonists Phase 4
9 Antiemetics Phase 4
10 Dermatologic Agents Phase 4
11
Histamine Phosphate Phase 4 51-74-1 65513
12 Histamine H1 Antagonists Phase 4
13 Anesthetics, Local Phase 4
14 Neurotransmitter Agents Phase 4
15 Immunoglobulins Phase 4
16 Antibodies Phase 4
17 Antitoxins Phase 4
18 Antibodies, Blocking Phase 4
19
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
21
Glycine Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 56-40-6 750
22 Antibodies, Monoclonal Phase 2, Phase 3
23 Citrate Phase 2, Phase 3
24
Glyburide Approved Phase 2 10238-21-8 3488
25
Ciprofloxacin Approved, Investigational Phase 2 85721-33-1 2764
26
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
27
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
28
Imidacloprid Vet_approved Phase 2 105827-78-9 86418
29 Hypoglycemic Agents Phase 2
30 Immunoglobulins, Intravenous Phase 1, Phase 2
31 Rho(D) Immune Globulin Phase 1, Phase 2
32 gamma-Globulins Phase 1, Phase 2
33 Immunoglobulin G Phase 2
34 Pharmaceutical Solutions Phase 2
35 Cytochrome P-450 Enzyme Inhibitors Phase 2
36 Anti-Infective Agents Phase 2
37 Anti-Bacterial Agents Phase 2
38 Antiparasitic Agents Phase 2
39 Antiprotozoal Agents Phase 2
40 Antibiotics, Antitubercular Phase 2
41 Antimalarials Phase 2
42 Antacids Phase 2
43 Adjuvants, Immunologic Phase 2
44 Anti-Ulcer Agents Phase 2
45 Gastrointestinal Agents Phase 2
46 Immunologic Factors Phase 2
47
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453
48
Carbon monoxide Approved, Investigational Phase 1 630-08-0 281
49
Diethylenetriamine Phase 1 111-40-0 8111
50 Antitubercular Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483) Completed NCT02339155 Phase 4 Diphenhydramine
2 A Randomized Trial for the Assessment of Immunogenicity and Safety of Four Different Dosing Regimens of BioThrax® for Post-Exposure Prophylaxis for Anthrax in Adults Completed NCT01641991 Phase 4
3 Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction Completed NCT00119067 Phase 4
4 A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis Not yet recruiting NCT03088111 Phase 4
5 A Phase 4, Open-label Field Study (200137) to Evaluate the Clinical Benefit, Safety and Pharmacokinetics in Subjects Treated With Raxibacumab (GSK3068483) Following Exposure to Bacillus Anthracis Not yet recruiting NCT02177721 Phase 4
6 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Completed NCT01491607 Phase 3
7 An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) Administered in Healthy Subjects Completed NCT02016963 Phase 2, Phase 3
8 A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults Active, not recruiting NCT03877926 Phase 3
9 A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema Unknown status NCT01794182 Phase 2 RP-1127 (Glyburide for Injection)
10 A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population Completed NCT00170469 Phase 2
11 A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects Completed NCT00170456 Phase 2
12 A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers Completed NCT00100724 Phase 2
13 A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers Completed NCT01770743 Phase 2
14 A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV) Completed NCT00845650 Phase 1, Phase 2
15 A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults Completed NCT01753115 Phase 2 Ciprofloxacin
16 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
17 Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax®) Without and With CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health Active, not recruiting NCT03518125 Phase 2 Sodium chloride injection USP, 0.9% (placebo)
18 A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-administering AV7909 With Ciprofloxacin or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults Active, not recruiting NCT04067011 Phase 2 Ciprofloxacin 500Mg Tablet;Doxycycline 100Mg Tablet
19 A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects Suspended NCT01624532 Phase 2 Normal Saline
20 A Phase II Study to Assess the Safety, Tolerability, Immunogenicity, and Optimal Primary Schedule of 3 Recombinant Protective Antigen (rPA) Anthrax Vaccines Administered in Two Intramuscular Doses to Healthy Adults Terminated NCT00133484 Phase 2
21 A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine Completed NCT00103467 Phase 1
22 A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults Completed NCT02239172 Phase 1
23 A Single Blind, Randomized, Placebo Control, Phase I Study to Evaluate the Safety and Immunogenicity of the GC1109 Administered by the Intramuscular Route in Healthy Men Completed NCT01867957 Phase 1
24 A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol) Completed NCT01979406 Phase 1
25 A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers Completed NCT02655549 Phase 1
26 A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers Completed NCT01202695 Phase 1 AVP-21D9;Placebo
27 Anthrax Vaccine Clinical Trials Completed NCT00114621 Phase 1 Anthrax Vaccine
28 A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults Completed NCT00057525 Phase 1
29 A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults Completed NCT01263691 Phase 1 Control
30 A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers Completed NCT01929226 Phase 1
31 A Phase I, Double-blind, Randomized, Placebo Controlled, Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) as a 120 Minute Infusion in Healthy, Normal Subjects Completed NCT01265745 Phase 1 Normal Saline for Injection
32 Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers. Completed NCT00448253 Phase 1
33 A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two Intramuscular Doses to Healthy Adults Completed NCT00063843 Phase 1
34 Randomized, Placebo-Controlled, Double Blind, Dose-Escalation Phase I Study of the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 [Anthim(TM)] and Its Potential Interaction With Ciprofloxacin Completed NCT00138411 Phase 1 Ciprofloxacin 500 mg;ETI-204 (Anthim)
35 A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers Completed NCT01932437 Phase 1
36 A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects Completed NCT01453907 Phase 1 ETI-204, "Anthim";placebo
37 A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
38 RV 151: A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults, WRAIR #984, HSRRB Log # A-11905. Completed NCT00412477 Phase 1
39 An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers Completed NCT01952444 Phase 1 Ciprofloxacin
40 A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Repeat Administration of Intravenous ETI-204 in Adult Volunteers Completed NCT01932242 Phase 1
41 A Double-blind, Randomized, Placebo-controlled, Study of the Safety and Immunogenicity of NasoShield Administered as One or Two Doses in Different Dosing Positions Recruiting NCT04415749 Phase 1
42 A Phase 1 Randomized, Observer-Blind, Active- and Placebo-Controlled Dose Comparison, Safety, Tolerability and Immunogenicity Study of Intranasal Adjuvanted Anthrax Vaccine (BW-1010; rPA + 20%W805EC) in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette With an Additional Unblinded Positive Control Arm Recruiting NCT04148118 Phase 1
43 First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield Active, not recruiting NCT03352466 Phase 1
44 A Phase I, Single Blind, Randomized, Placebo Controlled, Drug Interaction Study of Intravenous (IV) Valortim® and Intravenous (IV) Ciprofloxacin in Healthy, Normal Subjects Suspended NCT00964561 Phase 1 Ciprofloxacin and Valortim;Placebo Antibiotic and Valortim
45 A Phase I, Single Blind, Randomized, Placebo Controlled, Drug Interaction Study of Intravenous (IV) Valortim® and Intravenous (IV) Doxycycline in Healthy Normal Subjects Terminated NCT00964834 Phase 1 Doxycycline and Valortim;Placebo Antibiotic and Valortim;Placebo Antibiotic and Placebo Valortim
46 The Registry of Hyperbaric Oxygen Therapy Treated Patients Unknown status NCT02483650
47 Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin Completed NCT00031291 Anthrax Immune Globulin
48 Biomarkers in Necrotizing Soft Tissue Infections - Effects of Hyperbaric Oxygen Treatment on the Immune Response Completed NCT02501382
49 Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance Completed NCT01670435 Ciprofloxacin (BAYQ3939)
50 Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution Completed NCT01690559 Cipro (Ciprofloxacin, BAYQ3939)

Search NIH Clinical Center for Anthrax Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin

Cochrane evidence based reviews: anthrax

Genetic Tests for Anthrax Disease

Anatomical Context for Anthrax Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Anthrax Disease:

19
Skin, Lung Lymph Nodes, Gastrointestinal Tract

MalaCards organs/tissues related to Anthrax Disease:

40
Lung, Skin, Testes, Lymph Node, Neutrophil, T Cells, Endothelial

Publications for Anthrax Disease

Articles related to Anthrax Disease:

(show top 50) (show all 6250)
# Title Authors PMID Year
1
An informational reference on anthrax for first responders. 61 42
32441043 2020
2
Potential distributions of Bacillus anthracis and Bacillus cereus biovar anthracis causing anthrax in Africa. 42 61
32150557 2020
3
A cutaneous Anthrax outbreak in Koraput District of Odisha-India 2015. 61 42
32326927 2019
4
Endosomal recycling regulates Anthrax Toxin Receptor 1/Tumor Endothelial Marker 8-dependent cell spreading. 61 54
20382142 2010
5
Production of recombinant anthrax toxin receptor (ATR/CMG2) fused with human Fc in planta. 54 61
19796689 2010
6
Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis. 61 54
19901963 2010
7
Bacillus anthracis capsule activates caspase-1 and induces interleukin-1beta release from differentiated THP-1 and human monocyte-derived dendritic cells. 61 54
19737897 2010
8
Direct interaction between anthrax toxin receptor 1 and the actin cytoskeleton. 54 61
19817382 2009
9
Expression of Nlrp1b inflammasome components in human fibroblasts confers susceptibility to anthrax lethal toxin. 54 61
19651869 2009
10
Host-derived tumor endothelial marker 8 promotes the growth of melanoma. 54 61
19622764 2009
11
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. 61 54
19332539 2009
12
Modeling the activity of furin inhibitors using artificial neural network. 61 54
18977558 2009
13
Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins. 54 61
19377967 2009
14
The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor. 54 61
19049885 2009
15
Functional interactions between anthrax toxin receptors and the WNT signalling protein LRP6. 54 61
18717822 2008
16
Toxicity of anthrax toxin is influenced by receptor expression. 61 54
18596206 2008
17
Maturation modulates caspase-1-independent responses of dendritic cells to Anthrax lethal toxin. 61 54
18194483 2008
18
The effects of anthrax lethal factor on the macrophage proteome: potential activity on nitric oxide synthases. 54 61
18269913 2008
19
Anthrax lethal toxin increases superoxide production in murine neutrophils via differential effects on MAPK signaling pathways. 61 54
18322225 2008
20
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. 61 54
18319331 2008
21
Evidence against a human cell-specific role for LRP6 in anthrax toxin entry. 54 61
18350154 2008
22
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. 54 61
18172299 2008
23
Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways. 61 54
18413261 2008
24
Characterization of the interaction between anthrax toxin and its cellular receptors. 61 54
17381430 2007
25
Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells. 54 61
17251181 2007
26
Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation. 61 54
17389920 2007
27
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. 61 54
17335347 2007
28
Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. 54 61
17179036 2006
29
Divalent metal ion coordination by residue T118 of anthrax toxin receptor 2 is not essential for protective antigen binding. 61 54
17183731 2006
30
Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. 61 54
17054395 2006
31
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. 61 54
17041100 2006
32
LRP6 holds the key to the entry of anthrax toxin. 61 54
16564002 2006
33
Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. 61 54
16384550 2006
34
Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. 54 61
16299323 2005
35
In vivo protective role of human group IIa phospholipase A2 against experimental anthrax. 54 61
16272335 2005
36
Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets. 61 54
16170766 2005
37
Receptor-specific requirements for anthrax toxin delivery into cells. 61 54
16141341 2005
38
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. 54 61
16170021 2005
39
[Expression of ATR-Fc fusion protein in CHO cells]. 61 54
16285529 2005
40
Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. 61 54
16041026 2005
41
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. 54 61
15843553 2005
42
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin. 54 61
15381157 2005
43
Effects of dynamin inactivation on pathways of anthrax toxin uptake. 54 61
15511085 2004
44
Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. 54 61
15146199 2004
45
Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. 54 61
15044490 2004
46
The kindest cuts of all: crystal structures of Kex2 and furin reveal secrets of precursor processing. 54 61
15102434 2004
47
Prediction of proprotein convertase cleavage sites. 54 61
14985543 2004
48
Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. 61 54
14688144 2004
49
Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C. 61 54
14592973 2003
50
A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. 54 61
12788955 2003

Variations for Anthrax Disease

Expression for Anthrax Disease

Search GEO for disease gene expression data for Anthrax Disease.

Pathways for Anthrax Disease

Pathways related to Anthrax Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 PRDX1 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
2
Show member pathways
13.76 PLA2G2A MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2
3
Show member pathways
13.18 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
4
Show member pathways
13.17 PLA2G2A MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
5
Show member pathways
13.16 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
6
Show member pathways
13.15 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
7
Show member pathways
13.14 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
8
Show member pathways
13.1 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
9
Show member pathways
13.05 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
10
Show member pathways
13.04 PLA2G2A MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2
11
Show member pathways
13.04 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
12
Show member pathways
13.02 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
13
Show member pathways
12.99 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1 FURIN
14
Show member pathways
12.98 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
15
Show member pathways
12.97 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
16
Show member pathways
12.94 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
17
Show member pathways
12.92 PLA2G2A MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2
18 12.87 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
19
Show member pathways
12.85 PLA2G2A MAPK14 MAPK1 MAP2K3 MAP2K2 MAP2K1
20
Show member pathways
12.82 MAPK14 MAPK1 MAP2K4 MAP2K2 MAP2K1
21
Show member pathways
12.81 MAPK1 MAP2K4 MAP2K2 MAP2K1 CASP1
22
Show member pathways
12.79 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
23
Show member pathways
12.78 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
24
Show member pathways
12.78 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
25
Show member pathways
12.78 NLRP1 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2
26
Show member pathways
12.77 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
27
Show member pathways
12.76 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
28
Show member pathways
12.72 MAPK14 MAPK1 MAP2K3 MAP2K2 MAP2K1
29
Show member pathways
12.71 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
30
Show member pathways
12.68 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
31
Show member pathways
12.65 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
32
Show member pathways
12.62 MAPK14 MAPK1 MAP2K2 MAP2K1
33
Show member pathways
12.59 PLA2G2A MAPK1 MAP2K2 MAP2K1
34
Show member pathways
12.59 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
35
Show member pathways
12.58 MAPK1 MAP2K2 MAP2K1 LRP6
36
Show member pathways
12.57 PLA2G2A MAPK1 MAP2K2 MAP2K1
37
Show member pathways
12.57 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
38
Show member pathways
12.57 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
39
Show member pathways
12.56 MAPK14 MAPK1 MAP2K2 MAP2K1
40
Show member pathways
12.55 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
41
Show member pathways
12.54 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
42
Show member pathways
12.53 MAPK14 MAPK1 MAP2K3 MAP2K2 MAP2K1
43
Show member pathways
12.52 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
44
Show member pathways
12.52 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
45
Show member pathways
12.5 MAPK14 MAPK1 MAP2K2 MAP2K1
46
Show member pathways
12.49 MAPK14 MAPK1 MAP2K2 MAP2K1
47
Show member pathways
12.47 MAPK14 MAPK1 MAP2K4 MAP2K2 MAP2K1
48
Show member pathways
12.46 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
49
Show member pathways
12.45 MAPK14 MAPK1 MAP2K3 MAP2K2 MAP2K1
50 12.44 MAPK1 MAP2K4 MAP2K2 MAP2K1

GO Terms for Anthrax Disease

Cellular components related to Anthrax Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.03 PRDX1 NLRP1 MKKS MAPK14 MAPK1 MAP2K4
2 extracellular region GO:0005576 9.81 PLA2G2A PCSK6 MAPK14 MAPK1 MAP2K2 LRP6
3 early endosome GO:0005769 9.62 MAPK1 MAP2K2 MAP2K1 LRP6
4 endoplasmic reticulum GO:0005783 9.56 PLA2G2A PCSK6 MAP2K2 MAP2K1 LRP6 KIF1C
5 NLRP1 inflammasome complex GO:0072558 8.62 NLRP1 CASP1

Biological processes related to Anthrax Disease according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.05 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
2 protein phosphorylation GO:0006468 10.04 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
3 peptidyl-tyrosine phosphorylation GO:0018108 9.84 MAP2K4 MAP2K3 MAP2K2 MAP2K1
4 regulation of mitotic cell cycle GO:0007346 9.8 MAP2K4 MAP2K3 MAP2K2 MAP2K1
5 MAPK cascade GO:0000165 9.8 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
6 activation of protein kinase activity GO:0032147 9.78 MAP2K4 MAP2K3 MAP2K2 MAP2K1
7 toxin transport GO:1901998 9.72 LRP6 ANTXR2 ANTXR1
8 stress-activated protein kinase signaling cascade GO:0031098 9.71 MAP2K4 MAP2K3 MAP2K2 MAP2K1
9 ERK1 and ERK2 cascade GO:0070371 9.7 MAPK1 MAP2K2 MAP2K1
10 signal transduction by protein phosphorylation GO:0023014 9.67 MAP2K4 MAP2K3 MAP2K2 MAP2K1
11 response to muramyl dipeptide GO:0032495 9.64 NLRP1 MAPK14
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 MAP2K2 MAP2K1
13 negative regulation of hippo signaling GO:0035331 9.63 MAPK14 MAP2K3
14 face development GO:0060324 9.63 MKKS MAPK1 MAP2K1
15 secretion by cell GO:0032940 9.62 PCSK6 FURIN
16 reproductive process GO:0022414 9.62 ANTXR2 ANTXR1
17 Bergmann glial cell differentiation GO:0060020 9.61 MAPK1 MAP2K1
18 regulation of lipoprotein lipase activity GO:0051004 9.61 PCSK6 FURIN
19 regulation of ossification GO:0030278 9.61 MAPK14 MAPK1 LRP6
20 positive regulation of metallopeptidase activity GO:1905050 9.6 MAPK14 ANTXR1
21 p38MAPK cascade GO:0038066 9.59 MAPK14 MAP2K3
22 trachea formation GO:0060440 9.58 MAPK1 MAP2K1
23 nerve growth factor processing GO:0032455 9.56 PCSK6 FURIN
24 nerve growth factor production GO:0032902 9.51 PCSK6 FURIN
25 regulation of early endosome to late endosome transport GO:2000641 9.43 MAPK1 MAP2K2 MAP2K1
26 activation of MAPK activity GO:0000187 9.43 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
27 regulation of Golgi inheritance GO:0090170 9.33 MAPK1 MAP2K2 MAP2K1
28 regulation of stress-activated MAPK cascade GO:0032872 8.92 PRDX1 MAPK1 MAP2K2 MAP2K1

Molecular functions related to Anthrax Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.39 PRDX1 PCSK6 NLRP1 MKKS MAPK14 MAPK1
2 kinase activity GO:0016301 9.91 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
3 protein kinase activity GO:0004672 9.85 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
4 ATP binding GO:0005524 9.85 NLRP1 MKKS MAPK14 MAPK1 MAP2K4 MAP2K3
5 protein serine/threonine kinase activity GO:0004674 9.73 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1
6 nucleotide binding GO:0000166 9.7 NLRP1 MKKS MAPK14 MAPK1 MAP2K4 MAP2K3
7 endopeptidase activity GO:0004175 9.67 PCSK6 FURIN CASP1
8 protein tyrosine kinase activity GO:0004713 9.62 MAP2K4 MAP2K3 MAP2K2 MAP2K1
9 cysteine-type endopeptidase activator activity involved in apoptotic process GO:0008656 9.51 NLRP1 CASP1
10 MAP-kinase scaffold activity GO:0005078 9.48 MAP2K2 MAP2K1
11 nerve growth factor binding GO:0048406 9.4 PCSK6 FURIN
12 MAP kinase kinase activity GO:0004708 9.1 MAPK14 MAPK1 MAP2K4 MAP2K3 MAP2K2 MAP2K1

Sources for Anthrax Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....